

- Beyer, K. (1978). Discovery, development and delivery of new drugs. *Monographs in Pharmacology and Physiology*, No. 12. Spectrum, New York.
- FDA (Food and Drug Administration) (1987a). Good laboratory practice regulations: Final rule. 21 CFR Part 58, *Fed. Reg.*, September 4, 1987.
- FDA (Food and Drug Administration) (1987b). New drug, antibiotic, and biologic drug produce regulations. 21 CFR Parts 312, 314, 511, and 514, *Federal Register*, 52(53), 8798–8857.
- French, S. (1982). *Sequencing and Scheduling*. Halsted, New York.
- Gad, S. C. (2000). *Product Safety Evaluation Handbook*, 2nd ed. Marcel Dekker, New York.
- Goozner, M. (2004). *The \$800 Million Pill*. University of California Press, Los Angeles.
- Guarino, R. A. (1987). *New Drug Approval Process*. Marcel Dekker, New York.
- Hamner, C. E. (1982). *Drug Development*. CRC Press, Boca Raton, FL, pp. 53–80.
- Kliem, R. L. (1986). *The Secrets of Successful Project Management*. Wiley, New York.
- Knutson, J. R. (1980). *How to Be a Successful Project Manager*. American Management Associations, New York.
- Leber, P. (1987). FDA: The federal regulations of drug development. In H. Y. Meltzer (Ed.), *Psychopharmacology: The Third Generation of Progress*. Raven, New York, pp. 1675–1683.
- Levy, A. E., Simon, R. C., Beerman, T. H., Fold, R. M. (1977). Scheduling of toxicology protocol studies. *Comput. Biomed. Res.* 10, 139–151.
- Matoren, G. M. (1984). *The Clinical Process in the Pharmaceutical Industry*. Marcel Dekker, New York, pp. 273–284.
- Sneider, W. (1986). *Drug Development: From Laboratory to Clinic*. Wiley, New York.
- Spector, R., Park, G. D., Johnson, G. F., Vessell, E. S. (1988). Therapeutic drug monitoring. *Clin. Pharmacol. Therapeu.* 43, 345–353.
- Spilker, B. (1994). *Multinational Drug Companies*, 2nd ed. Raven, New York.
- Zbinden, G. (1992). *The Source of the River Po*. Haag and Herschen, Frankfurt, Germany.